Posted by Michael Wonder on 10 Oct 2024
PHARMAC improves access to three cancer medicines
10 October 2024 - PHARMAC will improve access to three cancer medicines from 1 November 2024.
The three medicines are cetuximab (Erbitux) for bowel cancer, bendamustine hydrochloride for relapsed or refractory chronic lymphocytic leukaemia and pemetrexed disodium heptahydrate, which is currently used for two types of cancer.
